Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza

Written by Kirsten Ruehl on 2nd May 2023. Posted in Client News.

• Previous
• Next